CHMP recommends nod of Merck Keytruda in combo with trastuzumab, chemotherapy to treat HER2-positive advanced GEJ adenocarcinoma expressing PD-L1

The recommendation is based on interim results from the Phase 3 KEYNOTE-811 trial, in which the KEYTRUDA regimen demonstrated a statistically significant improvement in progression-free survival (PFS) and objective response rate (ORR) compared to trastuzumab and chemotherapy alone in patients whose tumors expressed PD-L1 (CPS ≥1). In the study, more than 80% of patients had tumors that were PD-L1 positive. These PFS results will be presented at an upcoming medical meeting. The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected in the third quarter of 2023.

In May 2021, KEYTRUDA was approved in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in the U.S. This indication was approved by the FDA under accelerated approval based on ORR data from KEYNOTE-811, and continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. Merck is working with the FDA to update this indication to patients whose tumors are PD-L1 positive.

"Merck has an extensive clinical development program evaluating KEYTRUDA in gastrointestinal cancers and is continuing to study KEYTRUDA for multiple uses in gastric, hepatobiliary, esophageal, and colorectal cancers," the Company stated in a release.